枸杞补充剂12个月治疗延缓视网膜色素变性视锥细胞变性
结果显示枸杞组在90%和10%对比度最佳矫正视力上未出现恶化(p=0.001),且安慰剂组黄斑层变薄而枸杞组未见(p=0.008);但视野敏感度和全视野视网膜电图参数组间无显著差异。结论认为枸杞补充剂提供视网膜神经保护作用,可能延缓或最小化视锥细胞变性。
要点
- 枸杞组90%和10%对比度最佳矫正视力均未恶化,与安慰剂组差异显著(p=0.001)。
- 安慰剂组出现黄斑层变薄,枸杞组未见,组间差异显著(p=0.008)。
- 视野敏感度和全视野视网膜电图参数两组间无显著差异。
核心结论
- 枸杞补充剂对RP患者视网膜具有神经保护作用,可能延缓或最小化视锥细胞变性。
主要发现
- 两组依从率均超过80%;枸杞组90%和10%对比度最佳矫正视力未恶化,与安慰剂组差异显著(p=0.001)。
- 安慰剂组观察到黄斑层变薄,枸杞组未观察到,组间差异显著(p=0.008)。
- 两组间视野敏感度和全视野视网膜电图各参数均无显著差异。
- 治疗组未报告显著不良事件。
关键数值与推荐
- 主要结局为最佳矫正视力(90%和10%对比度)从基线至治疗结束的变化。
- 次要结局包括中心视野敏感度、全视野视网膜电图振幅(暗适应最大反应和明适应视锥反应)及平均黄斑厚度。
临床怎么用
- 对于视网膜色素变性患者,可考虑在12个月内每日补充枸杞颗粒以延缓视锥细胞变性相关的视力恶化。
- 需向患者说明枸杞补充对视野敏感度和视网膜电图参数未见显著改善。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Lycium barbarum L. (also known as "Goji berry"), a traditional Chinese herbal medicine, has been a common herb in the traditional Chinese pharmacopoeia for centuries. The main active component is the Lycium barbarum polysaccharides and its antioxidative effect has been widely shown to provide neuroprotection to the eye, and it would, therefore, be interesting to determine if Lycium barbarum help delay vision deterioration in patients with retinitis pigmentosa. AIM OF THE STUDY: Cone rescue is a potential method for delaying deterioration of visual function in Retinitis pigmentosa (RP). This study aimed to investigate the treatment effect of Lycium barbarum L. (LB) supplement on retinal functions and structure in RP patients after a 12-month intervention trial. METHODS: The investigation was a double-masked and placebo-controlled clinical study. Each of forty-two RP subjects who completed the 12-month intervention (23 and 19 in the treatment and placebo groups respectively) received a daily supply of LB or placebo granules for oral administration. The primary outcome was change of best corrected visual acuity (VA) (90% and 10% contrast) from the baseline to the end of treatment. The secondary outcomes were sensitivity changes of the central visual field, amplitude of full-field electroretinogram (ffERG) (including scotopic maximal response and photopic cone response), and average macular thickness. RESULTS: The compliance rates for both groups exceeded 80%. There were no deteriorations of either 90% or 10% contrast VA in the LB group compared with the placebo group (p = 0.001). A thinning of macular layer was observed in the placebo group, which was not observed in the LB group (p = 0.008). However, no significant differences were found in the sensitivity of visual field or in any parameters of ffERG between the two groups. No significant adverse effects were reported in the treatment group. CONCLUSIONS: LB supplement provides a neuroprotective effect for the retina and could help delay or minimize cone degeneration in RP. CLASSIFICATIONS: Clinical Studies (1.05). TRIAL REGISTRATION: clinicaltrials.gov Identifier NCT02244996.
引用
- Chan HH, Lam HI, Choi KY, et al. Delay of cone degeneration in retinitis pigmentosa using a 12-month treatment with Lycium barbarum supplement. J Ethnopharmacol. 2019. PMID: 30877066. doi:10.1016/j.jep.2019.03.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。